Drug Interactions between AccessPak for HIV PEP Basic and etravirine
This report displays the potential drug interactions for the following 2 drugs:
- AccessPak for HIV PEP Basic (emtricitabine/tenofovir disoproxil)
- etravirine
Interactions between your drugs
tenofovir etravirine
Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil) and etravirine
Coadministration with tenofovir may reduce the plasma concentrations of etravirine. The mechanism of interaction has not been described. In 23 study subjects administered etravirine with tenofovir disoproxil fumarate 300 mg once a day, etravirine peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) decreased by nearly 20% each. These changes were statistically, but not clinically, significant. Etravirine had no effect on the pharmacokinetics of tenofovir. Etravirine and tenofovir disoproxil fumarate may be coadministered without any dosage adjustments.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
Drug and food interactions
etravirine food
Applies to: etravirine
ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.
MANAGEMENT: Etravirine should always be administered following a meal.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
tenofovir food
Applies to: AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References (1)
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.